In Vitro & In Vivo Diagnostic Substances
Standard Industrial Classification: SIC 2835
Industry Insider Sentiment Analysis
The In Vitro & In Vivo Diagnostic Substances sector (SIC 2835) acts as a critical barometer for broader economic health. Our real-time monitoring reveals total transactions. Monitoring "cluster buying" is one of the most reliable leading indicators for future sector performance. By analyzing aggregate data across this specific Standard Industrial Classification, investors can filter out individual company volatility and identify high-conviction trends. When multiple directors and officers within the same industry move capital simultaneously, it often signals an upcoming sector-wide revaluation or a fundamental shift in supply chain dynamics that has yet to be recognized by the broader public market.
| Filing Date | Trade Date | Ticker | Company | Reporting Person | Relationship | Type | Price | Qty | Total, $ | Owned After |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026-03-09 20:24 | 2026-03-06 | TKNO | Alpha Teknova, Inc. | Gunstream Stephen | Director, Officer | BUY | $2.15 | 26,000 | $55,801 | 269,497 |
| 2026-03-09 23:03 | 2026-03-09 | MYGN | MYRIAD GENETICS INC | Raha Samraat S. | Director, Officer | BUY | $5.00 | 40,000 | $199,844 | 493,104 |
| 2026-03-09 20:30 | 2026-03-06 | TKNO | Alpha Teknova, Inc. | Lowell Matthew | Officer | BUY | $2.19 | 40,000 | $87,616 | 168,376 |
| 2026-03-06 01:01 | 2026-03-03 | IDXX | IDEXX LABORATORIES INC /DE | Hunt Nimrata | Officer | SELL | $634.57 | 1,758 | $1,115,577 | 18,141 |
| 2026-03-04 00:18 | 2026-03-02 | NTLA | Intellia Therapeutics, Inc. | BASTA JAMES | Officer | SELL | $13.78 | 1,211 | $16,688 | 156,794 |
| 2026-03-04 00:16 | 2026-03-02 | NTLA | Intellia Therapeutics, Inc. | Clark Eliana | Officer | SELL | $13.78 | 607 | $8,364 | 93,864 |
| 2026-03-03 01:00 | 2026-02-26 | IDXX | IDEXX LABORATORIES INC /DE | MAZELSKY JONATHAN JAY | Director, Officer | OPT+S | $657.55 | 23,326 | $15,338,081 | 83,606 |
| 2026-02-28 01:03 | 2026-02-26 | IDXX | IDEXX LABORATORIES INC /DE | Hunt Nimrata | Officer | SELL | $661.54 | 2,693 | $1,781,531 | 19,899 |
| 2026-02-28 00:46 | 2026-02-25 | MYGN | MYRIAD GENETICS INC | Phanstiel S. Louise | Director | BUY | $4.73 | 104,507 | $494,726 | 281,951 |
| 2026-02-20 02:00 | 2026-02-17 | IDXX | IDEXX LABORATORIES INC /DE | Vandebroek Sophie V. | Director | OPT+S | $628.62 | 1,464 | $920,293 | 648 |
| 2026-02-20 02:00 | 2026-02-17 | IDXX | IDEXX LABORATORIES INC /DE | Erickson Michael G | Officer | OPT+S | $627.38 | 5,371 | $3,369,666 | 12,693 |
| 2026-02-17 23:12 | 2026-02-17 | NEOG | NEOGEN CORP | Nassif Mikheal | Director, Officer | BUY | $10.94 | 23 | $252 | 704 |
| 2026-02-14 00:20 | 2026-02-13 | QDEL | QuidelOrtho Corp | Strobeck Matthew | Director | BUY | $23.96 | 10,000 | $239,586 | 27,775 |
| 2026-02-13 20:44 | 2026-02-13 | QDEL | QuidelOrtho Corp | Busky Joseph M. | Officer | BUY | $23.66 | 3,370 | $79,742 | 10,290 |
| 2026-02-13 18:43 | 2026-02-13 | QDEL | QuidelOrtho Corp | Blaser Brian J. | Officer | BUY | $23.59 | 10,540 | $248,661 | 40,073 |
| 2026-02-13 03:49 | 2026-02-10 | IMDX | Insight Molecular Diagnostics Inc. | BROADWOOD PARTNERS, L.P. | 10% owner | BUY | $5.75 | 521,739 | $2,999,999 | 11,931,839 |
| 2026-02-12 01:01 | 2026-02-10 | IDXX | IDEXX LABORATORIES INC /DE | FENNELL GEORGE | Officer | OPT+S | $646.72 | 11,345 | $7,336,993 | 9,823 |
| 2026-02-03 00:36 | 2026-01-26 | NEOG | NEOGEN CORP | Nassif Mikheal | Director, Officer | BUY | $9.93 | 49 | $486 | 681 |
| 2026-01-16 17:04 | 2026-01-16 | NEOG | NEOGEN CORP | Nassif Mikheal | Director, Officer | BUY | $9.33 | 137 | $1,279 | 632 |
| 2026-01-08 00:05 | 2026-01-05 | NTLA | Intellia Therapeutics, Inc. | Schultes Birgit C | Officer | SELL | $9.21 | 8,508 | $78,359 | 98,533 |
| 2026-01-08 00:05 | 2026-01-05 | NTLA | Intellia Therapeutics, Inc. | BASTA JAMES | Officer | SELL | $9.21 | 10,397 | $95,756 | 101,528 |
| 2026-01-08 00:04 | 2026-01-05 | NTLA | Intellia Therapeutics, Inc. | Lebwohl David | Officer | SELL | $9.21 | 11,903 | $109,627 | 121,249 |
| 2026-01-08 00:03 | 2026-01-05 | NTLA | Intellia Therapeutics, Inc. | Clark Eliana | Officer | SELL | $9.21 | 9,515 | $87,633 | 87,118 |
| 2026-01-08 00:02 | 2026-01-05 | NTLA | Intellia Therapeutics, Inc. | Dulac Edward J III | Officer | SELL | $9.21 | 6,379 | $58,751 | 99,683 |
| 2026-01-08 00:01 | 2026-01-05 | NTLA | Intellia Therapeutics, Inc. | Dube Michael P | Officer | SELL | $9.21 | 2,989 | $27,529 | 52,277 |
| 2026-01-08 00:05 | 2026-01-05 | NTLA | Intellia Therapeutics, Inc. | LEONARD JOHN M | Director, Officer | SELL | $9.21 | 34,146 | $314,485 | 1,013,339 |
| 2026-01-08 00:05 | 2026-01-05 | NTLA | Intellia Therapeutics, Inc. | Cohen Fred E | Director | BUY | $9.35 | 150,000 | $1,402,500 | 207,453 |
| 2025-12-13 00:09 | 2025-12-11 | NTLA | Intellia Therapeutics, Inc. | LEONARD JOHN M | Director, Officer | OPT+S | $9.49 | 88,146 | $836,382 | 1,038,928 |
| 2025-12-11 02:37 | 2025-12-10 | QDEL | QuidelOrtho Corp | RHOADS ANN D | Director | BUY | $28.28 | 750 | $21,206 | 15,021 |
| 2025-12-09 00:20 | 2025-12-04 | CLDX | Celldex Therapeutics, Inc. | Jimenez Freddy A. | Officer | SELL | $29.10 | 4,166 | $121,210 | 30,796 |
| 2025-12-05 00:11 | 2025-12-03 | ICCC | IMMUCELL CORP /DE/ | te Boekhorst Paul Francis Olivier | Director, Officer | BUY | $5.23 | 6,030 | $31,528 | 9,738 |
| 2025-12-04 00:14 | 2025-12-02 | ICCC | IMMUCELL CORP /DE/ | te Boekhorst Paul Francis Olivier | Director, Officer | BUY | $4.97 | 9,785 | $48,588 | 9,785 |
| 2025-12-02 00:33 | 2025-11-26 | QDEL | QuidelOrtho Corp | Wilkins Joseph D Jr. | Director | BUY | $27.96 | 370 | $10,343 | 11,876 |
| 2025-11-28 16:12 | 2025-11-25 | ICCC | IMMUCELL CORP /DE/ | Tomsche David Scott | Director | BUY | $4.76 | 3,266 | $15,554 | 4,740 |
| 2025-11-25 21:21 | 2025-11-24 | QDEL | QuidelOrtho Corp | Busky Joseph M. | Officer | BUY | $26.06 | 4,770 | $124,305 | 6,920 |
| 2025-11-26 00:16 | 2025-11-25 | QDEL | QuidelOrtho Corp | WIDDER KENNETH J | Director | OPT+S | $27.81 | 4,026 | $111,965 | 37,061 |
| 2025-11-25 00:09 | 2025-11-21 | QDEL | QuidelOrtho Corp | POLAN MARY LAKE PH D | Director | BUY | $22.43 | 1,000 | $22,430 | 12,640 |
| 2025-11-21 00:16 | 2025-11-19 | QDEL | QuidelOrtho Corp | Blaser Brian J. | Officer | BUY | $21.34 | 23,500 | $501,577 | 29,533 |
| 2025-11-18 00:17 | 2025-11-13 | CLDX | Celldex Therapeutics, Inc. | Wright Richard M. | OPT+S | $24.00 | 49,298 | $1,183,177 | 20,833 | |
| 2025-11-17 21:12 | - | VNRX | VOLITIONRX LTD | Reynolds Cameron John | Director, Officer | BUY | $0.35 | 20,000 | $7,000 | 2,554,847 |
| 2025-11-11 01:01 | 2025-11-07 | IDXX | IDEXX LABORATORIES INC /DE | Hunt Nimrata | Officer | OPT+S | $703.34 | 9,425 | $6,629,013 | 21,149 |
| 2025-11-07 20:20 | 2025-11-03 | NEOG | NEOGEN CORP | Nassif Mikheal | Director, Officer | BUY | $6.25 | 177 | $1,106 | 495 |
| 2025-10-15 23:05 | - | VNRX | VOLITIONRX LTD | Innes Guy Archibald | Director | BUY | $0.51 | 96,153 | $49,038 | 1,062,967 |
| 2025-10-15 23:05 | - | VNRX | VOLITIONRX LTD | Reynolds Cameron John | Director, Officer | BUY | $0.51 | 110,000 | $56,100 | 2,534,847 |
| 2025-10-15 23:05 | - | VNRX | VOLITIONRX LTD | STILL TIMOTHY I | Director | BUY | $0.51 | 48,076 | $24,519 | 1,535,458 |
| 2025-10-04 00:13 | 2025-10-01 | NTLA | Intellia Therapeutics, Inc. | Schultes Birgit C | Officer | SELL | $17.38 | 31 | $539 | 105,184 |
| 2025-10-04 00:13 | 2025-10-01 | NTLA | Intellia Therapeutics, Inc. | Dube Michael P | Officer | SELL | $17.38 | 1,871 | $32,518 | 55,266 |
| 2025-09-22 23:29 | 2025-09-18 | ACHV | ACHIEVE LIFE SCIENCES, INC. | Stewart Richard Alistair | Director, Officer | OPT+S | $2.92 | 129,501 | $378,143 | 228,875 |
| 2025-09-22 23:31 | 2025-09-18 | ACHV | ACHIEVE LIFE SCIENCES, INC. | Oki Mark K | Officer | OPT+S | $2.92 | 50,060 | $146,175 | 127,940 |
| 2025-09-20 00:26 | 2025-09-17 | AWHL | Aspira Women's Health Inc. | cohen Jeffrey k | Director | BUY | $0.45 | 55,556 | $25,000 | 375,697 |
Sector-Wide Insider Alpha
Analyzing insider movements across the In Vitro & In Vivo Diagnostic Substances sector provides a macro-view of executive conviction. When multiple leaders in different companies within the same SIC code (2835) simultaneously buy shares, it often indicates an industry-wide undervaluation or a positive shift in market cycles.
SEC Filings in In Vitro & In Vivo Diagnostic Substances
Every transaction in the In Vitro & In Vivo Diagnostic Substances industry is reported via Form 4 disclosures. By filtering these filings by industry, investors can detect institutional-scale sentiment shifts before they are reflected in broader market indices, following the capital flow of those with intimate industry knowledge.
UNDERSTANDING THE DATA
FILING DATE: The date and time when the transaction was reported to the SEC. This is when the public first receives the information.
TRADE DATE: The actual day the insider executed the purchase or sale in the market.
INDUSTRY: The specific market sector the company operates in. Useful for identifying broader institutional capital flows across sectors.
OWNED AFTER: The total number of shares held by the insider following the transaction. This highlights the insider's remaining conviction in the company.
CHANGE %: The percentage increase or decrease of the insider's total position. Large percentage changes often carry more weight than the dollar amount alone.
TRADE TYPES DEFINITIONS
BUY: An open market purchase. Typically indicates an insider's belief that the stock is undervalued or poised for growth.
SELL: An open market sale. While often used for diversification or liquidity, large or unexpected sales can be a warning signal.
OPT+S (OPTION EXERCISE & SALE): This occurs when an insider exercises their stock options and sells them immediately. Often part of a structured compensation plan.